EcoDrugPlus

Phospholipase A2 Group X

Ensembl ID : ENSOJAG00000009713
Gene Symbol: PLA2G10
1 Cross references
232 Possible Orthologues:

Phospholipase A2, Group Vii (Platelet-Activating Factor Acetylhydrolase, Plasma)

Ensembl ID : ENSOJAG00000009042
Gene Symbol: PLA2G7
1 Cross references
203 Possible Orthologues:

Phosphoribosylglycinamide Formyltransferase

Ensembl ID : ENSOJAG00000005857
Gene Symbol: GART
1 Cross references
246 Possible Orthologues:

Plasminogen

Ensembl ID : ENSOJAG00000022291
Gene Symbol: PLG
1 Cross references
253 Possible Orthologues:

Plasminogen Activator, Tissue Type

Ensembl ID : ENSOJAG00000001594
Gene Symbol: PLAT
1 Cross references
205 Possible Orthologues:

Platelet Activating Factor Receptor

Ensembl ID : ENSOJAG00000023231
Gene Symbol: PTAFR
1 Cross references
224 Possible Orthologues:

Platelet-Derived Growth Factor Receptor, Beta Polypeptide

Ensembl ID : ENSOJAG00000019027
Gene Symbol: PDGFRB
1 Cross references
198 Possible Orthologues:

Polo Like Kinase 1

Ensembl ID : ENSOJAG00000011874
Gene Symbol: PLK1
1 Cross references
188 Possible Orthologues:

Poly (Adp-Ribose) Polymerase 2

Ensembl ID : ENSOJAG00000011518
Gene Symbol: PARP2
1 Cross references
185 Possible Orthologues:

Poly (Adp-Ribose) Polymerase Family, Member 3

Ensembl ID : ENSOJAG00000008368
Gene Symbol: PARP3
1 Cross references
197 Possible Orthologues:

Porcupine O-Acyltransferase

Ensembl ID : ENSOJAG00000015491
Gene Symbol: PORCN
1 Cross references
193 Possible Orthologues:

Porcupine O-Acyltransferase Like

Ensembl ID : ENSOJAG00000011810
Gene Symbol: PORCNL
1 Cross references
197 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).